Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus CU 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus CU 7.
ANNOVERA vs CU-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
50 mg orally once daily
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Category C
Category C
Contraceptive
Contraceptive